Gastrointestinal Stromal Tumor Market: Future Growth Trends
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Does The Market Size Of The Gastrointestinal Stromal Tumor Market Compare Between 2026 And 2030?
The gastrointestinal stromal tumor market has demonstrated substantial growth in recent years. It is projected to expand from $1.36 billion in 2025 to $1.46 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.9%. This historical expansion can be attributed to factors like the approval of imatinib therapy, improved tumor classification, the expansion of oncology care centers, increased awareness of rare gi tumors, and the availability of surgical interventions.
The gastrointestinal stromal tumor market is projected to experience robust expansion over the coming years. By 2030, its valuation is anticipated to reach $1.98 billion, advancing at a compound annual growth rate (CAGR) of 8.0%. This projected growth is driven by factors such as the advancement of next-generation targeted treatments, an increase in precision diagnostics, a rise in clinical trial activities, the broadening scope of personalized cancer therapies, and enhanced patient survival rates. Key trends anticipated during this period encompass the growing application of targeted tyrosine kinase inhibitors, a heightened emphasis on molecular tumor profiling, the wider adoption of precision oncology strategies, an increase in combined surgical and drug therapies, and better long-term disease management.
Access Your Free Sample Report For In-Depth Market Analysis:
What Leading Drivers Are Supporting The Gastrointestinal Stromal Tumor Market Expansion?
The increasing occurrence of stomach cancer is anticipated to propel the growth of the gastrointestinal stromal tumor market. Stomach cancer refers to the uncontrolled multiplication of malignant cells in the lining of the stomach. While gastrointestinal stromal tumors (GISTs) can manifest in the stomach, they are distinct from stomach cancer. Patients with GISTs have been observed to have a heightened risk of developing additional cancers, including small bowel adenocarcinoma, especially when two separate tumors collide and merge. For instance, in January 2024, the American Cancer Society, a US-based professional organization, estimated approximately 26,890 new cases of stomach cancer and 10,880 deaths in the U.S. for 2024, accounting for 1.5% of all new cancer diagnoses. Thus, the rising incidence of stomach cancer is driving the expansion of the gastrointestinal stromal tumor market.
What Are The Main Segments Within The Gastrointestinal Stromal Tumor Market Segment Structure?
The gastrointestinal stromal tumor market covered in this report is segmented –
1) By Treatment Type: Chemotherapy, Targeted Therapy, Other Treatment Types
2) By Indication: Stomach, Small Intestine, Others Indications
3) By End-User: Hospitals, Clinics, Specialized Cancer Treatment Centers, Other End-Users
Subsegments:
1) By Chemotherapy: Traditional Chemotherapy Agents, Combination Chemotherapy Regimens
2) By Targeted Therapy: Tyrosine Kinase Inhibitors, Other Targeted Agents
3) By Other Treatment Types: Surgery, Radiation Therapy, Clinical Trials For Novel Therapies
What Emerging Trends Are Seen In The Gastrointestinal Stromal Tumor Market?
Major companies operating within the gastrointestinal stromal tumor market are developing innovative drugs, including those based on signal transduction and targeted therapy, to enhance treatment efficacy, tackle resistance to current therapies, and satisfy unmet clinical needs. Signal transduction and targeted therapy refer to treatments specifically designed to block or alter particular cellular signaling pathways that drive tumor proliferation and survival. For example, in November 2025, Ascentage Pharma Group International Inc., a China-based commercial-stage biopharmaceutical company, reported the publication of Phase Ib clinical data for olverembatinib (HQP1351) in Signal Transduction and Targeted Therapy, highlighting encouraging efficacy and safety in SDH-deficient gastrointestinal stromal tumors (GIST) and revealing a new antitumor mechanism involving lipid metabolism modulation.
Who Are The Companies Participating In The Gastrointestinal Stromal Tumor Market?
Major companies operating in the gastrointestinal stromal tumor market are Pfizer Inc., F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Merck & Co. Inc., GlaxoSmithKline plc, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca plc, Eli Lilly and Company, Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Sun Pharmaceutical Industries Limited, Jiangsu Hengrui Medicine Co. Ltd., Exelixis Inc., NATCO Pharma Ltd., Blueprint Medicines Corporation, Array BioPharma Inc., Deciphera Pharmaceuticals Inc., Ono Pharmaceutical Co. Ltd.
Get The Full Gastrointestinal Stromal Tumor Market Report:
Where Is The Gastrointestinal Stromal Tumor Market Most Concentrated Geographically?
North America was the largest region in the gastrointestinal stromal tumor market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal stromal tumor market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Gastrointestinal Stromal Tumor Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Gastrointestinal Stromal Tumor Market 2026, By The Business Research Company
Gastrointestinal Endoscopy Market Report 2026
https://www.thebusinessresearchcompany.com/report/gastrointestinal-endoscopy-global-market-report
Gastric Cancer Diagnostic Procedure Market Report 2026
Germ Cell Tumor Market Report 2026
https://www.thebusinessresearchcompany.com/report/germ-cell-tumor-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
